Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date (Ascending) Package Discontinuation Date Status
80725-0712-15 80725-0712 Dutasteride AVODART 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 15, 2022 In Use
69784-0712-04 69784-0712 Dutasteride AVODART 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 15, 2022 In Use
69784-0712-15 69784-0712 Dutasteride AVODART 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 15, 2022 In Use
42658-0021-92 42658-0021 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 19, 2022 In Use
51655-0972-21 51655-0972 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec. 21, 2022 In Use
51655-0972-53 51655-0972 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec. 21, 2022 In Use
51655-0972-54 51655-0972 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec. 21, 2022 In Use
60760-0654-10 60760-0654 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 22, 2022 In Use
50242-0159-01 50242-0159 Mosunetuzumab Lunsumio 1.0 mg/mL Immunotherapy Monoclonal Antibody CD20, CD3 Intravenous Dec. 22, 2022 In Use
50242-0142-01 50242-0142 Mosunetuzumab Lunsumio 30.0 mg/30mL Immunotherapy Monoclonal Antibody CD20, CD3 Intravenous Dec. 22, 2022 In Use

Found 10,000 results in 7 millisecondsExport these results